TABLE 2.
Serum HAI antibody titers and GMFRs in response to the A/H1N1, A/H3N2, and B virus strains in seronegative subjectsa
| Strain and treatment | nc | Geometric meanb HAI titer (95% CI)
|
GMFR (95% CI) | |
|---|---|---|---|---|
| Prevaccination | Postvaccination | |||
| A/H1N1 | ||||
| CAIV-T 107 | 33 | 2.04 (1.96, 2.13) | 3.92 (2.68, 5.73) | 1.92 (1.31, 2.81) |
| CAIV-T <105 | 29 | 2.00 (2.00, 2.00) | 2.31 (1.72, 3.10) | 1.15 (0.86, 1.55) |
| TIV | 30 | 2.00 (2.00, 2.00) | 2.89 (2.27, 3.69) | 1.45 (1.14, 1.84) |
| Placebo | 30 | 2.00 (2.00, 2.00) | 2.52 (1.85, 3.42) | 1.26 (0.93, 1.71) |
| A/H3N2 | ||||
| CAIV-T 107 | 33 | 2.13 (1.98, 2.29) | 23.35 (13.91, 39.20) | 10.96 (6.63, 18.13) |
| CAIV-T <105 | 34 | 2.13 (1.98, 2.28) | 2.72 (1.98, 3.73) | 1.28 (0.92, 1.77) |
| TIV | 35 | 2.04 (1.96, 2.12) | 3.35 (2.58, 4.34) | 1.64 (1.27, 2.12) |
| Placebo | 34 | 2.17 (2.00, 2.35) | 2.72 (2.01, 3.66) | 1.25 (0.92, 1.70) |
| B | ||||
| CAIV-T 107 | 27 | 2.27 (2.04, 2.53) | 15.59 (9.18, 26.48) | 6.86 (3.98, 11.83) |
| CAIV-T <105 | 21 | 2.14 (1.94, 2.35) | 3.74 (2.19, 6.40) | 1.75 (1.01, 3.04) |
| TIV | 26 | 2.23 (3.01, 2.47) | 3.60 (2.23, 5.81) | 1.62 (1.06, 2.45) |
| Placebo | 24 | 2.31 (2.05, 2.61) | 4.62 (2.77, 7.70) | 2.00 (1.18, 3.38) |
a
A subject was seronegative to a particular strain if his or her prevaccination HAI titer to that strain was ≤1:4.
b
Geometric mean, antilog of the mean of the log-transformed titer or fold rise.
c
n, number of subjects in the calculation.